Sino Biopharmaceutical Limited (SBHMY)
Sino Biopharmaceutical Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Hong Kong, HK. The stock last traded at $13.01, up 0.00% on the session, giving a market capitalisation of $11.56B. On trailing twelve-month figures it carries a trailing P/E of 32.50, a net margin of 7.4%. Its beta of 0.60 implies it has historically moved less than the broad market.
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited is most often compared with the following Healthcare names: